Carnegie Investment Counsel Acquires 15,710 Shares of Astera Labs, Inc. $ALAB

Carnegie Investment Counsel increased its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 26.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,119 shares of the company’s stock after buying an additional 15,710 shares during the period. Carnegie Investment Counsel’s holdings in Astera Labs were worth $8,343,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Astera Labs in the 4th quarter worth $18,708,000. Nordea Investment Management AB purchased a new position in shares of Astera Labs during the fourth quarter valued at $2,028,000. Swedbank AB increased its stake in shares of Astera Labs by 76.8% during the fourth quarter. Swedbank AB now owns 78,140 shares of the company’s stock valued at $12,999,000 after buying an additional 33,940 shares during the period. Numerai GP LLC raised its holdings in shares of Astera Labs by 153.1% in the third quarter. Numerai GP LLC now owns 13,212 shares of the company’s stock valued at $2,587,000 after acquiring an additional 7,992 shares in the last quarter. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. bought a new stake in shares of Astera Labs in the fourth quarter valued at about $499,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Bethany Mayer sold 686 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $395.04, for a total transaction of $270,997.44. Following the sale, the director directly owned 5,550 shares of the company’s stock, valued at $2,192,472. The trade was a 11.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack R. Lazar sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $355.17, for a total value of $3,551,700.00. Following the sale, the director owned 75,688 shares in the company, valued at approximately $26,882,106.96. The trade was a 11.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,040,691 shares of company stock worth $507,675,380 over the last ninety days. Company insiders own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Rothschild & Co Redburn initiated coverage on shares of Astera Labs in a research note on Friday, May 1st. They issued a “neutral” rating and a $153.00 price objective for the company. Roth Capital reissued a “buy” rating and set a $275.00 target price on shares of Astera Labs in a research report on Wednesday, May 6th. Needham & Company LLC boosted their price target on shares of Astera Labs from $220.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Evercore reaffirmed an “outperform” rating and issued a $297.00 price target on shares of Astera Labs in a research report on Tuesday, May 19th. Finally, UBS Group increased their price objective on shares of Astera Labs from $205.00 to $400.00 and gave the company a “neutral” rating in a research note on Monday, June 29th. Twelve research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.75.

Astera Labs Price Performance

Shares of ALAB stock opened at $412.97 on Monday. The stock’s fifty day moving average price is $335.76 and its 200 day moving average price is $214.94. Astera Labs, Inc. has a 1-year low of $88.18 and a 1-year high of $499.48. The company has a market cap of $70.79 billion, a price-to-earnings ratio of 279.03, a price-to-earnings-growth ratio of 4.65 and a beta of 3.66.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.07. Astera Labs had a return on equity of 18.49% and a net margin of 26.72%.The business had revenue of $308.36 million for the quarter, compared to analyst estimates of $292.19 million. During the same quarter in the previous year, the firm earned $0.33 earnings per share. The company’s revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. As a group, equities research analysts anticipate that Astera Labs, Inc. will post 1.88 earnings per share for the current year.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.